12:00 AM
 | 
Aug 02, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ARQ 197: Phase II started

Kyowa Hakko began an Asian Phase II trial evaluating oral ARQ 197 in 30 patients. The start triggered a $5 million milestone payment to ArQule from Kyowa Hakko, which...

Read the full 124 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >